Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort.

Hepatol Commun · 2024 · PMC11537570 · PMID 39495153

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significancep =0.14not close (p > 0.1)

Changes in bilirubin levels, although more pronounced in the AZ/BV group, did not reach statistical significance (−17.0 μmol/L±50.5 vs. −10.4 μmol/L±29.3, p =0.14).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.